dc.contributor.author
Lechner, Katharina
dc.contributor.author
Scherr, Johannes
dc.contributor.author
Lorenz, Elke
dc.contributor.author
Lechner, Benjamin
dc.contributor.author
Haller, Bernhard
dc.contributor.author
Krannich, Alexander
dc.contributor.author
Halle, Martin
dc.contributor.author
Wachter, Rolf
dc.contributor.author
Duvinage, André
dc.contributor.author
Edelmann, Frank
dc.date.accessioned
2023-08-09T11:27:12Z
dc.date.available
2023-08-09T11:27:12Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/40388
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-40109
dc.description.abstract
Objectives: To evaluate associations of omega-3 fatty acid (O3-FA) blood levels with cardiometabolic risk markers, functional capacity and cardiac function/morphology in patients with heart failure with preserved ejection fraction (HFpEF).
Background O3-FA have been linked to reduced risk for HF and associated phenotypic traits in experimental/clinical studies.
Methods: This is a cross-sectional analysis of data from the Aldo-DHF-RCT. From 422 patients, the omega-3-index (O3I = EPA + DHA) was analyzed at baseline in n = 404 using the HS-Omega-3-Index(R) methodology. Patient characteristics were; 67 +/- 8 years, 53% female, NYHA II/III (87/13%), ejection fraction >= 50%, E/e ' 7.1 +/- 1.5; median NT-proBNP 158 ng/L (IQR 82-298). Pearson's correlation coefficient and multiple linear regression analyses, using sex and age as covariates, were used to describe associations of the O3I with metabolic phenotype, functional capacity, echocardiographic markers for LVDF, and neurohumoral activation at baseline/12 months.
Results: The O3I was below (< 8%), within (8-11%), and higher (> 11%) than the target range in 374 (93%), 29 (7%), and 1 (0.2%) patients, respectively. Mean O3I was 5.7 +/- 1.7%. The O3I was inversely associated with HbA1c (r = - 0.139, p = 0.006), triglycerides-to-HDL-C ratio (r = - 0.12, p = 0.017), triglycerides (r = - 0.117, p = 0.02), non-HDL-C (r = - 0.101, p = 0.044), body-mass-index (r = - 0.149, p = 0.003), waist circumference (r = - 0.121, p = 0.015), waist-to-height ratio (r = - 0.141, p = 0.005), and positively associated with submaximal aerobic capacity (r = 0.113, p = 0.023) and LVEF (r = 0.211, p < 0.001) at baseline. Higher O3I at baseline was predictive of submaximal aerobic capacity (beta = 15.614, p < 0,001), maximal aerobic capacity (beta = 0.399, p = 0.005) and LVEF (beta = 0.698, p = 0.007) at 12 months.
Conclusions: Higher O3I was associated with a more favorable cardiometabolic risk profile and predictive of higher submaximal/maximal aerobic capacity and lower BMI/truncal adiposity in HFpEF patients. Graphic abstract Omega-3 fatty acid blood levels are inversely associated with cardiometabolic risk factors in HFpEF patients. Higher O3I was associated with a more favorable cardiometabolic risk profile and aerobic capacity (left) but did not correlate with echocardiographic markers for left ventricular diastolic function or neurohumoral activation (right). An O3I-driven intervention trial might be warranted to answer the question whether O3-FA in therapeutic doses (with the target O3I 8-11%) impact on echocardiographic markers for left ventricular diastolic function and neurohumoral activation in patients with HFpEF. This figure contains modified images from Servier Medical Art () licensed by a Creative Commons Attribution 3.0 Unported License.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Omega-3 fatty acids
en
dc.subject
Omega-3 index
en
dc.subject
Eicosapentaenoic acid
en
dc.subject
Docosahexaenoic acid
en
dc.subject
Heart failure
en
dc.subject
Diastolic dysfunction
en
dc.subject
Metabolic phenotype
en
dc.subject
Atherogenic dyslipidemia
en
dc.subject
Functional capacity
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Omega-3 fatty acid blood levels are inversely associated with cardiometabolic risk factors in HFpEF patients: the Aldo-DHF randomized controlled trial
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1007/s00392-021-01925-9
dcterms.bibliographicCitation.journaltitle
Clinical Research in Cardiology
dcterms.bibliographicCitation.number
3
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.pagestart
308
dcterms.bibliographicCitation.pageend
321
dcterms.bibliographicCitation.volume
111
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
34453204
dcterms.isPartOf.issn
1861-0684
dcterms.isPartOf.eissn
1861-0692